Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell

Blood (2023) 142 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2023-181602

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jennifer L Crombie, Austin I Kim, Nancy L. Bartlett, Robert A. Redd, Victoria Patterson, Celeste Carey, Sobana Balasubramanian, Oreofe O. Odejide, Reid W. Merryman, Ann LaCasce, Caron A Jacobson, Eric Jacobsen, Erin M Parry, David C Fisher, Alex F. Herrera, Matthew S Davids, Margaret A. Shipp, Philippe Armand, Geoffrey P. Shouse

Blood (2023) 142 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2023-181067

Published: 2023

Journal Articles

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Blood (2023) 142 (Supplement 1): 104.

https://doi.org/10.1182/blood-2023-180242

Published: 2023

Journal Articles

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2023-182204

Published: 2023

Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2023-173103

Published: 2023

Journal Articles

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inhye E Ahn, Yinglu Zhou, Svitlana Tyekucheva, Hannah Cormier, Stacey M Fernandes, Josie Montegaard, Marykate Kilcommons, Jennifer L Crombie, Reid W. Merryman, Erin M Parry, Philippe Armand, David C Fisher, Caron A Jacobson, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2023-180788

Published: 2023

Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Christine E. Ryan, Jennifer L. Crombie, Svitlana Tyekucheva, Mikaela M. McDonough, Josie S. Montegaard, Austin I. Kim, Jacob D. Soumerai, Alvaro J. Alencar, Shruti Bhandari, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2022) 140 (Supplement 1): 9871–9872.

https://doi.org/10.1182/blood-2022-169986

Published: 2022

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6531–6533.

https://doi.org/10.1182/blood-2022-159823

Published: 2022

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

David Qualls, Michael J Buege, Phuong Dao, Paolo F. Caimi, Sarah C. Rutherford, Graham Wehmeyer, Jason T. Romancik, Lori A. Leslie, Mwanasha H. Merrill, Jennifer L. Crombie, Behzad Amoozgar, Brad S. Kahl, David A. Bond, Kami J. Maddocks, Michelle Okwali, Venkatraman Seshan, Gilles Salles, Connie Lee Batlevi

Blood (2022) 140 (Supplement 1): 787–789.

https://doi.org/10.1182/blood-2022-167620

Published: 2022

Journal Articles

Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy

Jennifer L. Crombie, Robert A. Redd, Victor A. Chow, Jordan Gauthier, Erin Mullane, Geoffrey Shouse, Alex F. Herrera, Jason Romancik, Jonathon B. Cohen, Anna Saucier, Roch Houot, Caron Jacobson, Philippe Armand, Brian T. Hess

Blood (2021) 138 (Supplement 1): 886.

https://doi.org/10.1182/blood-2021-152819

Published: 2021

Journal Articles

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2021-147263

Published: 2021

Journal Articles

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Sushanth Gouni, Allison C. Rosenthal, Jennifer L. Crombie, Andrew Ip, Manali Kamdar, Brian T. Hess, Lei Feng, Grace Watson, Amy Ayers, Sattva S. Neelapu, Arushi Khurana, Madiha Iqbal, Yi Lin, Reid W Merryman, Paolo Strati

Blood (2021) 138 (Supplement 1): 2495.

https://doi.org/10.1182/blood-2021-147591

Published: 2021

Journal Articles

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

Blood (2021) 138 (Supplement 1): 640.

https://doi.org/10.1182/blood-2021-146624

Published: 2021

Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139864

Published: 2020

Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Zixu Wang, MS, Alexandra Savell, BS, Lisa Brennan, RN, BSN, Jessica Lowney, Karen Francoeur, RN, Josie Montegaard, NP, Austin I. Kim, MD, Jacob D. Soumerai, MD, Jon E. Arnason, MD, Allan Louie Cruz, MD, Sigrid Berg, MD, David C. Fisher, MD, Jennifer R Brown, MD PhD, Matthew S. Davids, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-138811

Published: 2020

NARROW

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only